Kornimate/medical-research-clean huggingface dataset:
effect of supplementation with ω-3 fatty acids, vitamin d and calcium in patients with acute lymphoblastic leukemia.

Conditions: Acute Lymphoblastic Leukemia; Vitamin d Deficiency

Summary: the purpose of this study is to evaluate the efficacy of supplementation with omega 3, vitamin d and calcium, in a cohort of children with all undergoing treatment and compare changes in the concentrations of biomarkers of bone resorption (trap5b, ctx, and rankl), the rankl/opg ratio, and biomarkers of bone formation (balp, oc, pinp, picp and opg) after 6 and 12 weeks of supplementation.

in pediatric hematological patients, the administration of high and prolonged doses of corticosteroids has a negative effect on bone metabolism, causing a significant reduction in bone mineral density (bmd). maintaining adequate levels of vitamin d (vd) and calcium is crucial for bone health, and deficiencies in these nutrients increase the risk of osteoporosis. children with acute lymphoblastic leukemia (all) have been found to have a high prevalence of vd deficiency. bone turnover markers (btms) are substances produced by osteoblasts and osteoclasts that provide information about the dynamic remodeling of bone. limited research has investigated the role of btms in pediatric all patients receiving vd supplementation. emerging evidence suggests that long-chain ω-3 polyunsaturated fatty acids (lcpufa-ω3) play a significant role in bone health. consumption of eicosapentaenoic acid (epa) and docosahexaenoic acid (dha) may inhibit bone resorption and promote bone formation in humans. currently, there are no randomized controlled clinical trials comparing the effects of combined supplementation with lcpufa-ω3, vd, and calcium on btms in children with cancer.

Eligibility criteria:
inclusion criteria: * children with acute lymphoblastic leukemia in maintenance * authorization from both parents or legal guardian for recruiting of the child into the study with consent have been explained * must be able to swallow capsules exclusion criteria: * patients with acute or chronic renal failure * added pathology * fish hypersensitivity * down´s syndrome

Keywords: acute lymphoblastic leukemia bone turnover biomarkers corticosteroids bone mineral density long-chain polyunsaturated fatty acids n-3 fatty acids vitamin d
a yoga program for breast cancer patients undergoing chemotherapy

Conditions: Fatigue; Sleep Disturbances

Summary: the primary aim of this study is to assess and compare change in qol during chemotherapy as measured by the functional assessment of cancer therapy-breast (fact-breast) score between patients receiving yoga and those not receiving yoga. secondary endpoints will include other measures of qol such as sleep quality measured with the pittsburg sleep quality inventory (psqi), anxiety and depression using hospital anxiety and depression scale (hads), and adherence to yoga and to chemotherapy treatment.


Eligibility criteria:
inclusion criteria: * age\>18 years * history of stage i-iii breast cancer * patient scheduled to receive or within 2 weeks of receiving intravenous chemotherapy for their breast cancers * eastern cooperative oncology group performance status of \<3 * ability to understand english 5.2 exclusion criteria: * planning to start yoga on their own within the next 12 weeks * maintained a regular personal practice or yoga within the 3 months before enrolling onto the study * severe chronic obstructive pulmonary disease * class iii or iv heart failure * child c cirrhosis * end-stage renal disease exclusion criteria: * planning to start yoga on their own within the next 12 weeks * maintained a regular personal practice or yoga within the 3 months before enrolling onto the study * severe chronic obstructive pulmonary disease * class iii or iv heart failure * child c cirrhosis * end-stage renal disease
maestro handheld cardiac monitor validation

Conditions: Cardiac Arrhythmia

Summary: the purpose of this study is to demonstrate that the maestro hand held heart monitor can accurately diagnose atrial fibrillation, atrial flutter or normal sinus rhythm in patients.

the purpose of this study is to determine if maestro can be used to detect heart arrhythmias, specifically atrial fibrillation in humans. maestro will be used to measure heart rate and rhythm at the same time that patients are being monitored with a standard 3, 5, or 12 lead electrocardiogram (ecg) in a clinical setting. the recorded maestro results will be compared to the ecg results to assess maestro's accuracy. data will be analyzed by a pass/fail criterial. the data will be downloaded and printed for the investigators' interpretation who will first review and code the data from meastro, blinded to the ecg findings. then the investigators will interpret the ecg findings and the 2 sets of data will be compared. the ecg result is the true value with which to compare the maestro result.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent exclusion criteria: * implanted pacemakers * open wounds or abrasions on their hands * prior damage to hands or thumbs precluding obtaining an ecg tracing
"awareness, preconception, and fear of epidural analgesia among childbearing women in saudi arabia."

Conditions: Assess Women Awareness and Fear About EDA for Labor

Summary: the aim of our study is to measure the level of awareness, preconceptions, and level of fear regarding epidural analgesia among childbearing women in kkuh in riyadh.

this research was designed as a hospital-based observational cross-sectional study conducted at king khalid university hospital, using a self-administered questionnaire based on previous research.22-24-26 approved by the institutional review board at king saud university, college of medicine, riyadh, saudi arabia on 08.august.2022 ref. no. 22/0592/irb. the sample included pregnant women attending an obstetrical clinic for routine antenatal follow-up, and the data collection was conducted during the month of august 2022. the questionnaire included five parts (sociodemographic, preconception, awareness, fear, and desirability). a total of 26 questions with multiple-choice answers. the sample size was determined using the comrey and lee criterion comrey and lee (1992) stated that a 200-sample size is acceptable. the questionnaire was completed by 202 participants who met the inclusion criteria that is being a pregnant woman and completing the survey, and the exclusion criteria were non-pregnant women and an incomplete survey. the data collectors made it clear to the participants that taking part in the study was completely optional, and the participants signed anonymous consent forms.

Eligibility criteria:
inclusion criteria: * pregnant woman * completing the survey exclusion criteria: * non-pregnant women * incomplete survey

Keywords: awareness, preconception, fear, epidural analgesia, labor pain
nutritional evaluation of patients with congestive heart failure

Conditions: Congestive Heart Failure

Summary: this study objective is to assess the nutritional status of patients with congestive heart failure.


Eligibility criteria:
inclusion criteria: * congestive heart failure patients between tne ages 40 to 90,all stages of the disease. exclusion criteria: * non

Keywords: congestive heart failure energy expenditure body composition caloric intake
treatment of age-related macular degeneration using retinal stem and progenitor cells

Conditions: Age-Related Macular Degeneration

Summary: treatment of age-related macular degeneration using retinal stem and progenitor cells

the aim of the project is to develop a biomedical cell product based on retinal pigment epithelium cells for highly effective treatment age-related macular degeneration; to conduct the clinical trials of the biomedical cell product in the treatment of age-related macular degeneration.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of age-related macular degeneration * the patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation * written informed consent exclusion criteria: * the presence of any malignant tumor within the last 5 years * acute or chronic diseases in the stage of decompensation * chronic infectious diseases: hiv, viral hepatitis b, c, tuberculosis * patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods * chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol * patients are unable or unwilling to give written informed consent and / or follow research procedures * any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study
clinical features of covid-19 patients

Conditions: Covid19; Acute Respiratory Distress Syndrome; Ventilatory Failure

Summary: the data were retrospectively collected during the first and the second wave of epidemic in covid-19 patients with severe acute respiratory syndrome coronavirus 2, at the moment of intensive care unit admission and during the in intensive care unit staying.

at the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans, arterial blood gas parameters (ph, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation), and pain assessed by using numeric rating scale.

Eligibility criteria:
inclusion criteria: * covid-19 patients * acute respiratory distress syndrome * needing of ventilatory support exclusion criteria: * asymptomatic covid-19 patients * few symptoms * mild symptoms * without needing of ventilatory support
bovine lactoferrin and antibiotic-associated diarrhoea.

Conditions: Antibiotic Associated Diarrhoea

Summary: this prospective, randomized, parallel-group, double blind, single-center study is to be conducted in the medical university of warsaw public paediatric teaching hospital in following departments: department of paediatric gastroenterology and nutrition, department of paediatrics and nephrology, department of pediatric pneumonology and allergy, department of pediatrics with medical assessment unit, admissions department. it is planned to include a total of 156 children aged between 12 months to 18 years old receiving antibiotic therapy because of acute respiratory tract infection/or urinary tract infection. the children will be randomly assigned to receive 100 mg of bovine lactoferrin or placebo twice a day orally for the whole period of antibiotic therapy. the primary efficacy parameter is occurrence of diarrhea during the antibiotic therapy and two weeks after, defined as \> 3 stools a day, a watery or loose stool with/or occurrence of blood in the stool.


Eligibility criteria:
inclusion criteria: * acute respiratory or urinary infection requiring empiric antibiotic therapy. * antibiotic treatment started before 24 hours prior to enrollment. * the consent of parents or legal guardians to participate in the study exclusion criteria: * severe or generalized bacterial infection * antibiotic therapy during the last 8 weeks * use of probiotic during the seven days prior to enrollment * immune disorders, * chronic disease of the gastrointestinal tract, * actual acute or chronic diarrhea, * intake of iron supplementation, * cows milk protein allergy * lack of consent of the parents or legal guardians to participate in the study.

Keywords: lactoferrin clostridium difficile antibiotic associated diarrhoea children antibiotic therapy diarrhoea
clinical investigation of proton treatment in hodgkin lymphoma patients - pro-hodgkin

Conditions: Hodgkin Lymphoma

Summary: hodgkin lymphoma patients with limited stage are commonly cured with limited chemotherapy followed by radiotherapy. studies have shown a risk of late toxicity from the radiotherapy, such as second cancer, heart failure and lung toxicity. with proton therapy the dose to normal tissue can be minimised without compromising the dose to the tumor. the aim of our study is to investigate whether proton therapy can be delivered in a safe way to hodgkin lymphoma patients with less late side effects than conventional radiotherapy, while retaining the high cure rate. this is a multicentre phase ii study of pbs proton beam therapy in patients ≤60 years, with early stage hodgkin lymphoma treated with induction chemotherapy. the study is performed in a non-inferiority setting comparing with a historical population-based consecutive swedish material. the control group was treated according to the same principles, except that the radiotherapy was delivered with photons.


Eligibility criteria:
inclusion criteria: * histological diagnosis of classic hodgkin lymphoma. * ann arbour stage 1a, 1b or 2a. * both patients with and without risk factors, i.e. bulky disease, erythrocyte sedimentation rate (esr)\>50, more than two involved sites. * supra diaphragmal disease. * age 18-60 years. * eastern cooperative oncology group (ecog) performance status 0 - 2. * initial staging positron emission tomography/computed tomography (pet/ct). * induction chemotherapy including 2 cycles of abvd for patients without risk factors and 4 cycles of abvd for patients with risk factors. * for patients with risk factors a ct after 2 abvd confirming complete remission (cr) or partial remission (pr). for patients without risk factors clinical response is sufficient at inclusion, but a ct scan is recommended before start of radiotherapy. * radiotherapy (rt) start not later than 6 weeks after end of chemotherapy. * written informed consent obtained prior to any study specific procedures. * women of reproductive age must agree to use contraceptives during the study treatment period. exclusion criteria: * pregnancy. * serious concomitant systemic disorder endangering treatment delivery. * more than 5mm tumour motion on 4 dimensional computed tomography (4dct) unless deep inspiration breath hold (dibh) is used. not applicable if target is located outside mediastinum or photon treatment is planned. * clinical or radiographic stable disease (sd)/ progressive disease (pd) during induction chemotherapy. * not able to comply with treatment and study procedures. * no additional active malignancy except indolent lymphoma in the bone marrow, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer.

Keywords: proton therapy
study of hmpl-760 plus r-gemox versus placebo plus r-gemox in relapsed/refractory dlbcl

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Summary: the goal of this study is to evaluate the efficacy of hmpl-760 in combination with r-gemox versus placebo in combination with r-gemox in patients with relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl).

a phase ii randomized, controlled study to evaluate the efficacy, safety, and pharmacokinetics of hmpl-760 in combination with r-gemox versus placebo in combination with r-gemox in patients with relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl). the study phases include screening period, treatment period, safety observation period, pfs follow-up period, and os follow-up period.

Eligibility criteria:
inclusion criteria: 1. sign the informed consent form(icf) and be able to follow the requirements of study protocol; 2. age ≥18 years; 3. eastern cooperative oncology group (ecog) performance status between 0 and 2; 4. histopathologically confirmed diagnosis of dlbcl; 5. the investigator judges that the patient's current condition requires further treatment; 6. patients should have at least one bi-dimensionally measurable lesion; 7. expected survival is more than 12 weeks; exclusion criteria: 1. patients with known primary or secondary central nervous system lymphoma (cnsl) or the presence of clinical symptoms suggestive of cnsl; 2. women who are pregnant (positive pregnancy test during the screening period) or breastfeeding; 3. organ insufficiency; 4. currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (hiv), hepatitis b virus (hbv), or hepatitis c virus (hcv): 5. history of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug; 6. known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin k antagonist (warfarin); 7. toxicities from prior anticancer therapy not resolved to grade ≤ 1 (except for alopecia and decreased appetite); 8. clinically significant active infection;

Keywords: r-gemox r/r dlbcl hmpl-760
the efficacy and safety of repetitive transcranial magnetic stimulation for upper-limb motor function recovery in subcortical and brainstem stroke

Conditions: Stroke; Hemiplegia; Subcortical Infarction

Summary: the purpose of this study is to evaluate the efficacy and safety of repetitive transcranial magnetic stimulation applied with an electromagnetic therapy stimulator 'altms-a' for upper-limb motor function recovery with the sham control group for those who need upper-limb rehabilitation treatment for subcortical and brainstem stroke

after low-frequency repetitive transcranial magnetic stimulation (rtms) over the contralesional motor cortex (m1), the score of the box and block test increased immediately, especially in patients without cortical involvement. eighty-eight patients will be recruited and divided into two groups. each group will receive 10 sessions of the real rtms or sham rtms over the contralesional primary motor cortex. each rtms session consists of low-frequency (1hz) 1800 stimulations. the objective of this study is to evaluate the efficacy and safety of rtms for upper-limb motor function in patients with subcortical and brainstem stroke.

Eligibility criteria:
inclusion criteria: * 19-80 years old * radiologically confirmed ischemic stroke with subcortical and brainstem lesions within 90 days * fugl-meyer assessment scale (upper extremity) \> 15 * mini-mental status exam (the korean version) \> 14 with appropriate cognitive function * written informed consent exclusion criteria: * fugl-meyer assessment scale (wrist) \< 1 or fugl-meyer assessment scale (hand) \< 1 * hemorrhagic stroke or traumatic brain injury * cerebellar stroke * previous history of stroke * traumatic brain injury * previous history of brain surgery * need for intensive care due to complications associated with stroke (e.g. pneumonia, infection, hemodynamic instability) * history of psychological or neurological diseases * history of pain or muscular weakness of upper limbs which may interfere with rehabilitation * history of seizure or epilepsy * aphasia * skin lesions in the stimulation site of scalp * intracranial metal implant * inability to receive regular physical or occupational therapy * disagreement to use contraception in women of childbearing age

Keywords: stroke transcranial magnetic stimulation rehabilitation neuronal plasticity subcortical infarction
neuromodulation therapy for task-specific dystonia

Conditions: Isolated Focal Hand Dystonia

Summary: this study aims to apply a non-invasive brain stimulation technology called repetitive transcranial magnetic stimulation (rtms) in patients with focal hand dystonia (fhd). the goal of the study is to identify which cortical target (premotor cortex (pmc) or primary somatosensory cortex (psc)) will show benefit after active rtms compared to sham rtms. a secondary goal of the study is to understand if 10 hz rtms can show behavioral benefit compared to sham rtms. the study will evaluate rtms response using measures if writing on a sensor tablet, examiner and patient dystonia rating scales and brain imaging scan (functional mri) to understand brain changes after rtms. safety measures include adherence to tms guidelines and thorough medical screening to prevent seizures.

the primary objective of this study is to develop rtms for fhd. the focus is to assess whether stimulating the pmc or psc will show greater improvement in writing behavior. this research builds upon prior studies that have demonstrated improvement in behavior after rtms to pmc and psc. the study includes five sequential visits: * visit 1 behavior writing measures and dystonia rating scales. * visit 2 includes task-based functional mri brain scans to develop cortical target for rtms sessions. * visits 3, 4, and 5: fhd participants receive 10 hz rtms to pmc, psc and sham rtms to pmc in a cross over design with at minimum one week of washout between sessions. participants complete behavior writing measures and rating scales on same day before and after each tms session and an fmri after each tms session. up to 5 healthy volunteers were recruited to help develop the tms visits. the information in this record reflects visits 2-5

Eligibility criteria:
inclusion criteria: * healthy control participants: 1. 18yrs and older 2. left or right hand dominance 3. age-matched to focal hand dystonia patients 4. must be able to sign informed consent 5. must be literate * focal hand dystonia patients: 1. 18yrs and older 2. left or right hand dominance 3. diagnosed with writer's cramp dystonia in left or right hand 4. must be able to sign informed consent 5. must be literate exclusion criteria: healthy control participants (visits 2, 3, 4, and 5) and focal hand dystonia patients (visits 2, 3, 4, and 5): 1. other neurological movement disorders diagnoses including other types of dystonia, parkinsonism, or essential tremor 2. botulinum toxin injections within 3 months of research study 3. medications with effects on the central nervous system including anticholinergic, benzodiazepines, and muscle relaxants among others within 1 week of the study 4. no physical or occupational therapy of the upper extremities 5. any contraindications to mri (ie: metal in body or implanted medical devices, etc) 6. any contraindication on tms adult safety screening (tass form) including seizure history, pregnancy, brain injury, cranial metal implants, known structural brain lesion